Abstracts tagged "physical function"

Abstract Number: 322 • 2013 ACR/ARHP Annual Meeting
Ustekinumab Improves Physical Function, Quality Of Life, and Work Productivity Of Patients With Active Psoriatic Arthritis Who Were Methotrexate-naïve Or Previously Treated With Methotrexate Or Anti-Tumor Necrosis Factor Agent:Data From 2 Phase 3, Randomized, Placebo-Controlled Trials
Proton Rahman¹, Lluis Puig², Alice B. Gottlieb³, Arthur Kavanaugh⁴, Iain B. McInnes⁵, Christopher T. Ritchlin⁶, Shu Li⁷, Yuhua Wang⁷, Ning Zhao⁸, Rita Ganguly⁸, Michael Song⁷, Alan M. Mendelsohn⁹ and Chenglong Han⁸, ¹Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²Universitat Autònoma de Barcelona, Barcelona, Spain, ³Tufts Medical Center, Boston, MA, ⁴University of California, San Diego, La Jolla, CA, ⁵Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁶Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁷Janssen Research & Development, LLC., Spring House, PA, ⁸Janssen Global Services, LLC., Malvern, PA, ⁹Immunology, Janssen Research & Development, LLC., Spring House, PA
Background/Purpose: To examine the impact of ustekinumab (UST) treatment on patient reported outcomes in patients with active psoriatic arthritis (PsA) using week 24 data from…
Abstract Number: 1889 • 2012 ACR/ARHP Annual Meeting
The Effects of Physical & Mental Health Rehabilitation Program (PMHRP) for Hemophilic Arthritis Patients
Won Sook BAK¹, Myung Chul Yoo¹, Nam Su Cho¹, Sang Hack Lee², Yoon Hee Kim³ and Ki Young Yoo¹, ¹Arthritis & Rheumatism Center, Kyung Hee University Hospital at Gangdong, Seoul, South Korea, ²Hemophilia Center, Kyung Hee University Hospital at Gangdong, Seoul, South Korea, ³Kyung Hee University, Seoul, South Korea
Background/Purpose: Most of the rehabilitation program for patients with hemophilic arthritis are focused on only the improvement of physical activities. However, the actual hemophilic arthritis…
Abstract Number: 392 • 2012 ACR/ARHP Annual Meeting
Analysis of Factors Impact On Patient Global Assessment in Daily Practice Based On Observational Cohort IORRA (Institute of Rheumatology, Rheumatoid Arthritis)
Yasushi Inoue¹, Eiichi Tanaka², Ayako Nakajima³, Eisuke Inoue⁴, Akiko Kobayashi⁴, Daisuke Hoshi¹, Naoki Sugimoto⁴, Kumi Shidara⁴, Yohei Seto⁴, Atsuo Taniguchi⁴, Shigeki Momohara¹ and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Tokyo Women's Medical University, Tokyo, Japan, ³Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ⁴Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Patient global assessment (PtGA) is an element of the new ACR/EULAR remission criteria for rheumatoid arthritis (RA). This definition has been reported to better…
Abstract Number: 400 • 2012 ACR/ARHP Annual Meeting
High Patient Global Assessment Scores Associate with the Residual Disease Activity Unidentified by a 28-Joint Examination in Rheumatoid Arthritis Patients Approaching Clinical Remission
Yasushi Inoue¹, Eiichi Tanaka², Ayako Nakajima³, Eisuke Inoue⁴, Akiko Kobayashi⁴, Daisuke Hoshi¹, Naoki Sugimoto⁴, Kumi Shidara⁴, Yohei Seto⁴, Atsuo Taniguchi⁴, Shigeki Momohara¹ and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Tokyo Women's Medical University, Tokyo, Japan, ³Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ⁴Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Patient global assessment (PtGA) is a component of the new ACR/EULAR remission criteria for rheumatoid arthritis (RA). It has been reported that >50% of…
Abstract Number: 371 • 2012 ACR/ARHP Annual Meeting
Treat-to-Target Strategy Aiming At Achievement of Structural and Functional Remission in Patients with Active Elderly-Onset Rheumatoid Arthritis
Takahiko Sugihara¹, Tatsuro Ishizaki², Tadashi Hosoya¹, Shoko Iga¹, Waka Yokoyama¹, Fumio Hirano¹, Nobuyuki Miyasaka³ and Masayoshi Harigai⁴, ¹Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ²Human Care Research Team, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan, ³Department of Medicine and Rheumatology and Global Center of Excellence Program, Tokyo Medical and Dental University, Tokyo, Japan, ⁴Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan
Background/Purpose: Treat-to-target is the consensus treatment strategy for patients with rheumatoid arthritis (RA), but supporting evidence for treat-to-target strategy in elderly RA patients in clinical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].